跳转至内容
Merck
CN
所有图片(1)

主要文件

219372

Sigma-Aldrich

组织蛋白酶G抑制剂I

≥98% (HPLC), solid, cathepsin G inhibitor, Calbiochem®

别名:

组织蛋白酶G抑制剂I

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C36H33N2O6P
分子量:
620.63
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

产品名称

组织蛋白酶G抑制剂I, The Cathepsin G Inhibitor I, also referenced under CAS 429676-93-7, controls the biological activity of Cathepsin G. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

质量水平

方案

≥98% (HPLC)

表单

solid

效能

53 nM IC50

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

颜色

white

溶解性

DMSO: 5 mg/mL
methanol: soluble

运输

ambient

储存温度

−20°C

SMILES字符串

[P](=O)(O)(O)C(c5c6c(ccc5)cccc6)C(=O)c1cc2c(cc1C(=O)N(C3CCN(CC3)C(=O)c4ccccc4)C)cccc2

InChI

1S/C36H33N2O6P/c1-37(28-18-20-38(21-19-28)35(40)25-11-3-2-4-12-25)36(41)32-23-27-14-6-5-13-26(27)22-31(32)33(39)34(45(42,43)44)30-17-9-15-24-10-7-8-16-29(24)30/h2-17,22-23,28,34H,18-21H2,1H3,(H2,42,43,44)

InChI key

GNOZQRKYZJSIPZ-UHFFFAOYSA-N

一般描述

组织蛋白酶G的有效,选择性,可逆,竞争性非肽抑制剂[IC50=53 nM,Ki=63 nM]。弱抑制胰凝乳蛋白酶(Ki = 1.5 µM),弱抑制凝血酶,Xa因子,IXa因子,纤溶酶,胰蛋白酶,类胰蛋白酶,蛋白酶3和人白细胞弹性蛋白酶(IC50 >100 µM)。
组织蛋白酶G的有效,选择性,可逆,竞争性非肽抑制剂(IC50 = 53 nM,Ki = 63 nM)。弱抑制胰凝乳蛋白酶(Ki = 1.5 µM),对凝血酶,Xa因子,IXa因子,纤溶酶,胰蛋白酶,类胰蛋白酶,蛋白酶3和人白细胞弹性蛋白酶(IC50 >100 µM)没有任何明显的抑制作用。

生化/生理作用

主要靶标
组织蛋白酶G
产物不与ATP竞争。
可逆性:是
细胞渗透性:否
靶标Ki:63 nM,对于组织蛋白酶G

包装

用惰性气体包装

警告

毒性:标准处理(A)

重悬

复溶后,等分并冷冻(-20°C)。储备液在-20°C条件下可稳定保存3个月。

其他说明

Greco, M.N., et al. 2002.J. Am. Chem. Soc.124, 3810.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Mira Tohmé et al.
Methods in molecular biology (Clifton, N.J.), 960, 509-515 (2013-01-19)
Proteases generate peptides that bind to MHC class II molecules to interact with a wide diversity of CD4(+) T cells. They are expressed in dedicated organelles: endosomes and lysosomes of professional antigen presenting cells (pAPCs) such as B cells, macrophages
Stefan J Schunk et al.
Circulation, 144(11), 893-908 (2021-07-02)
Cardiovascular diseases and chronic kidney disease (CKD) are highly prevalent, aggravate each other, and account for substantial mortality. Both conditions are characterized by activation of the innate immune system. The alarmin interleukin-1α (IL-1α) is expressed in a variety of cell
Hui Yang et al.
EMBO reports, 24(10), e57032-e57032 (2023-08-31)
Bromodomain-containing protein 4 (BRD4) is overexpressed and functionally implicated in various myeloid malignancies. However, the role of BRD4 in normal hematopoiesis remains largely unknown. Here, utilizing an inducible Brd4 knockout mouse model, we find that deletion of Brd4 (Brd4Δ/Δ )
Fabian Gärtner et al.
ACS omega, 5(43), 28233-28238 (2020-11-10)
During an immune response, cathepsin G (CatG) takes on the role of adaptive and innate immunity and the outcome depends on the localization of CatG. Soluble, cell surface-bound, or intracellular CatG is also responsible for pathophysiology conditions. We applied the
Akmaral Assylbekova et al.
Pharmaceuticals (Basel, Switzerland), 15(5) (2022-05-29)
Coronavirus disease 2019 (COVID-19) can lead to multi-organ failure influenced by comorbidities and age. Binding of the severe acute respiratory syndrome coronavirus 2 spike protein (SARS-CoV-2 S protein) to angiotensin-converting enzyme 2 (ACE2), along with proteolytic digestion of the S

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门